Fundraising FoxMESA VERDE VENTURE PARTNERS — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Immix Biopharmaimmixbio.cominMay 2024
Immix Biopharma is a clinical-stage biopharmaceutical company developing NXC-201, a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL amyloidosis and other plasma cell-driven immune diseases.
BiotechHealthtechLos Angeles, US
Gabriel Morris(Chief Financial Officer)inIlya Rachman(Founder & Chief Executive Officer)inDavid Marks(Chief Medical Officer)
BoardCarey Ng(Director)Magda Marquet(Director)Jane Buchan(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.